Roche Xeloda To Be Reimbursed By Medicare As Prodrug Of 5-FU
Executive Summary
Roche's oral treatment for late-stage metastatic breast cancer Xeloda (capecitabine) will be covered for outpatient use by Medicare effective Jan. 1, 1999, the company announced Jan 13.
You may also be interested in...
Roche Xeloda Medicare Part B Reimbursement Raised To 90% Of AWP
Roche's oncologic Xeloda will be reimbursed at 90% of the average wholesale price under Medicare Part B
Roche Xeloda Medicare Part B Reimbursement Raised To 90% Of AWP
Roche's oncologic Xeloda will be reimbursed at 90% of the average wholesale price under Medicare Part B
Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing
Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich